Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and for cancer supportive care by targeting high value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancers and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizerâs palbociclib (IbranceÂŽ) for the treatment of MDM2-amplified advanced solid cancers, and in an upcoming Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Emerging ALRN-6924 clinical and substantial preclinical data support its use across multiple cancer types as a combination therapy with targeted agents, chemotherapies, and immuno-oncology drugs. Aileron Therapeutics is exploring collaboration opportunities regarding ALRN-6924 and for its research in areas such as targeted protein degradation, HIF1-Îą, and the Bcl-2 family of cancer targets. Source
No articles found.
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
DURECT is a biopharmaceutical company actively developing therapeutics based on it...
DURECT is a biopharmaceutical company actively ...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the de...
Kala Pharmaceuticals, Inc. (Kala) is a biopharm...
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...
Oncolytics is focused on obtaining regulatory a...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...
Join the National Investor Network and get the latest information with your interests in mind.